Therefore, P-gp inhibitors have been studied as enhancers of oral absorption of drugs that are P-gp substrates. We investigated the in vitro and in vivo P-gp inhibitory activity of synthesized xanthone analogues. With 3-(3-chloro-2-hydroxypropoxy)-1-hydroxy-9H-thioxanthen-9-one, compound 13, accumulation of daunomycin (DNM) increased 707% and efflux of DNM decreased 66% compared to DNM alone. Relative
肠道P-糖蛋白(P-gp)是口服药物吸收的限制步骤。因此,已经研究了P-gp
抑制剂作为P-gp底物的药物的口服吸收的增强剂。我们研究了合成的
蒽酮类似物的体外和体内P-gp抑制活性。与单独的DNM相比,使用3-(3-
氯-2-羟基丙氧基)-1-羟基-9 H-
噻吨黄酮9-one化合物13时,
道诺霉素(DNM)的积累增加了707%,而DNM的流出减少了66%。口服
紫杉醇(
PTX,25 mg / kg)的相对
生物利用度(RB)与13(5 mg / kg)相比增加了2.5倍。在异种移植动物模型中,口服
PTX(40 mg / kg)与13(10 mg / kg)显着抑制肿瘤生长,并且比单独静脉注射
PTX(10 mg / kg)更有效。因此,合成的x吨
酮类似物13对于口服吸收P-gp底物抗癌药可能具有治疗益处。